title: Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012.
abstract: We present early estimates of influenza vaccine effectiveness (VE) in the population targeted for vaccination, during 25 December 2011 to 19 February 2012. The adjusted VE was 55% (95% CI: 3 to 79) against any type of influenza virus and 54% (95% CI: 1 to 79) against influenza A(H3N2) virus. This suggests a moderate protective effect of the vaccine in the targeted population in a late influenza epidemic with limited match between vaccine and circulating strains.
authors.affiliation: National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain. sjimenezj@isciii.es
authors.forename: S
authors.initials: S
authors.lastname: Jimenez-Jorge
authors.forename: S
authors.initials: S
authors.lastname: de Mateo
authors.forename: F
authors.initials: F
authors.lastname: Pozo
authors.forename: I
authors.initials: I
authors.lastname: Casas
authors.forename: M
authors.initials: M
authors.lastname: Garcia Cenoz
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.forename: V
authors.initials: V
authors.lastname: Gallardo
authors.forename: E
authors.initials: E
authors.lastname: Perez
authors.forename: T
authors.initials: T
authors.lastname: Vega
authors.forename: C
authors.initials: C
authors.lastname: Rodriguez
authors.forename: C
authors.initials: C
authors.lastname: Quinones
authors.forename: E
authors.initials: E
authors.lastname: Martinez
authors.forename: J
authors.initials: J
authors.lastname: Gimenez
authors.forename: Jm
authors.initials: J
authors.lastname: Vanrell
authors.forename: D
authors.initials: D
authors.lastname: Castrillejo
authors.forename: Mc
authors.initials: M
authors.lastname: Serrano
authors.forename: Jm
authors.initials: J
authors.lastname: Ramos
authors.forename: A
authors.initials: A
authors.lastname: Larrauri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D018571:Sentinel Surveillance; D013030:Spain / Q000453:epidemiology; D014611:Vaccination; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines